Sample Scenario — Executive Misconduct & Insider Risk Simulation

The Halcyon Founder Crisis Exercise

A branching, choose-your-path tabletop built for a founder-led AI chip company. The CEO is the company's strategy, its public face, and its most privileged user — and he has just been linked to a suspected foreign intelligence asset. Six shared injects establish the crisis, then the board's own decision — bring the government in now, or finish its own investigation first — sends the exercise down one of two independent, fully-scripted paths. Neither one lets the board stay in the background.

16injects per path
2diverging paths
10 dayssimulated timeline
3.5 hrstypical runtime

Fictional, but built to feel real in the room.

Every detail below is fictional — specific enough to feel real in the room, and generic enough to map onto any organization where one executive holds the strategy, the relationships, and the keys to everything.

Halcyon Silicon

A publicly traded designer of AI accelerators and data center networking chips, headquartered in San Jose, with ~38,000 employees and one of the largest market capitalizations in the world. Its founder has been CEO for 28 years, owns 3.5% of the company, and personally holds the relationships with its largest customers, suppliers, and government counterparts. Its most advanced chips are subject to U.S. export controls, and new export licenses are reviewed product by product.

Halcyon has never had a named successor, because it has never needed one. Its stock is already down 18% from its peak on fears about AI spending. Its security program was built to protect the company from outsiders. It was never designed around the possibility that the most targeted person in the company would be the one at the top.

The Founder-CEO — 28 years in role, 3.5% shareholder
The Lead Independent Director — former defense official
Stratos Data Systems — Singapore cloud customer, under export-control investigation
Federal government — export licenses pending, congressional oversight

The crisis everyone faces.

Six injects, delivered over the first 39 hours, that every player experiences regardless of what the board ultimately decides. This phase ends with the decision that splits the exercise in two.

DAY 0
18:30
INJECT 1Detection

A story about the CEO, not the company

A national newspaper tells Halcyon's head of communications it will publish tomorrow: U.S. intelligence agencies reportedly concluded that a senior executive at Stratos Data Systems — with whom the CEO had a personal relationship — was working for a foreign intelligence service. The reporter wants comment by 6 a.m.

Tests: who is told first when the subject of the story is the CEO — and how fast the lead independent director is in the loop.
21:00
INJECT 2Admission

"It was personal. Nothing was shared."

The CEO tells the general counsel and the lead independent director that the relationship was real and romantic, lasted about eighteen months, and ended in the spring. He insists he never shared anything confidential. He wants to send a note to all employees tonight admitting the affair, before the story runs.

Tests: who controls the response when the CEO's personal interests and the company's diverge — and whether his note gets reviewed before it goes out.
DAY 1
07:00
INJECT 3Market / media

Published, and down 9% before the open

The story runs, and it adds a detail Halcyon didn't expect: Stratos is part of a federal investigation into whether export-controlled chips were diverted abroad. Halcyon shares fall 9% in premarket trading. Major customers start calling their account teams.

Tests: communications when the facts belong to someone else's investigation and the stock is reacting faster than the company can.
11:00
INJECT 4Insider risk

The most privileged user

The CISO reviews the CEO's access. During a trip to Singapore last year, an unrecognized device logged into his account from a hotel network. His executive assistant also routinely shared his calendar — including product roadmap review dates — with Stratos staff to arrange meetings.

Tests: running an insider-risk review on the person who outranks everyone conducting it.
16:00
INJECT 5Government

Three committees and a pending license

Three congressional committee chairs ask the CEO for a closed-door briefing within ten days. Export-control officials ask Halcyon for its full shipment history with Stratos. A license for Halcyon's next-generation accelerator is under government review.

Tests: managing several government stakeholders at once — who speaks, what they say, and whether it stays consistent.
DAY 2
09:00
INJECT 6Decision point

Bring the government in now, or finish the investigation first

The board's special committee and outside counsel present two options. Engage now: brief federal counterintelligence officials, share the security team's findings as they develop, and accept the congressional briefing date. Or investigate first: complete a privileged independent review — about six weeks — before sharing findings, and offer Congress a later date. The CEO strongly prefers the second. The board has to decide.

Tests: national security cooperation versus control of the process — with the CEO's preference in the room and his conduct under review. This is the fork.

The board decides. The exercise branches.

INJECTS 1–6 DECISION A — ENGAGE NOW B — INVESTIGATE FIRST

From here, the facilitator runs one of two fully independent scripts depending on what the board chose in Inject 6. Toggle between them below to see how each one unfolds — in a live session, players only ever see the one they earned.

Path A — the board brings the government in nowTen injects. Engaging early buys credibility, not control — and once the government has the facts, the board no longer decides what happens to them.
DAY 2
15:00
INJECT 7ACooperation

They want his devices

Halcyon's outside counsel and the lead independent director meet with federal counterintelligence officials. The government asks for forensic images of the CEO's phone and laptop. The CEO's personal lawyer objects: the devices hold years of family and personal data.

Tests: the line between the company's cooperation and the CEO's personal rights — and whether he has his own counsel yet.
DAY 3
10:00
INJECT 8ALeak

"Possible breach at the top"

Within a day, details of Halcyon's briefing leak to the press — including the hotel login. The headline calls it a possible breach at the top of America's most strategic chip company. Shares fall another 6%.

Tests: communicating facts you shared in confidence, once they're public and framed by someone else.
15:00
INJECT 9ACustomers

"Was our data exposed?"

Security teams at two of Halcyon's largest cloud customers demand written assurance that their joint design and roadmap data wasn't exposed. One pauses a joint engineering review until it gets an answer.

Tests: what you can tell customers during an active government matter — and what you owe them anyway.
DAY 4
11:00
INJECT 10AEmployees

Agents in the building

Federal agents interview members of the export-compliance team. Employees ask HR whether they need their own lawyers. An internal post — "Are we the ones being investigated?" — gets thousands of views.

Tests: supporting employees through a government interview process, including clear guidance on whom the company's lawyers represent.
DAY 5
16:00
INJECT 11AForensics

Eleven minutes in the board portal

Forensics traces the hotel login to the CEO's credentials being used on an unrecognized laptop for eleven minutes. During that session, someone viewed a board pre-read that included the next two years of the product roadmap.

Tests: turning a forensic finding into a decision about materiality, notification, and disclosure.
DAY 6
09:00
INJECT 12ADisclosure

Disclosure over the CEO's objection

Counsel advises that the portal access may need to be disclosed to investors as a cybersecurity matter. The CEO argues that disclosing it would end his career over eleven minutes nobody can explain. The disclosure committee includes two of his direct reports.

Tests: whether a disclosure decision can be made independently of the person it affects most.
DAY 7
14:00
INJECT 13ACongress

"Incomplete"

The CEO gives the closed-door congressional briefing. Afterward, a committee member tells reporters his answers about the timeline of the relationship were "incomplete" and asks for a follow-up in writing.

Tests: preparation and consistency — and who owns the record of what the CEO has said, to whom, and when.
DAY 8
10:00
INJECT 14ABusiness impact

The license goes on hold

The export license for Halcyon's next-generation accelerator is placed on hold pending review. About $6B in customer orders depend on it, and two customers ask whether they should place orders with a competitor instead.

Tests: absorbing the business cost of cooperation without reversing the decision that caused it.
DAY 9
09:00
INJECT 15ADecision point

The interim findings

The special committee's interim findings: no evidence the CEO knowingly shared confidential information. But he violated Halcyon's insider-risk policy by never reporting a close relationship with an executive at a customer, and his credentials were used to access board material. The board must decide: keep him as CEO with restrictions on his access, travel, and devices; place him on leave; or begin a transition. The board has to decide.

Tests: proportionate accountability for a founder — what has been proven, what hasn't, and what the company can live with either way.
DAY 10
11:00
INJECT 16ASuccession

Nobody is next

Three of Halcyon's largest institutional shareholders ask the board to publicly disclose a CEO succession plan within 30 days. The board has never formally named one, and the two internal candidates report directly to the CEO.

Tests: separating the immediate leadership question from the key-person risk the crisis exposed.
Path B — the board finishes its investigation firstTen injects. Waiting buys control, not time — and every fact the board learns privately is a fact the government will later ask why it wasn't told.
DAY 2
14:00
INJECT 7BGovernment

A polite letter, published

Halcyon writes to the committee chairs offering a briefing "upon completion of the independent review." Within hours, the committee publishes the letter alongside a statement accusing the company of stalling on a national security matter.

Tests: how a reasonable process request reads once someone else decides how to present it.
DAY 3
09:00
INJECT 8BGovernment

The license goes on hold anyway

Export-control officials place the license for Halcyon's next-generation accelerator on hold and open a formal inquiry into the company's dealings with Stratos. About $6B in customer orders depend on that license.

Tests: whether waiting actually protected the business — and how to respond when it didn't.
17:00
INJECT 9BPolitical

Praise, then a resignation call

Senior administration officials publicly praise the CEO as a national asset. The next day, a senator calls for him to resign. Halcyon is now being cited by both sides of a political argument it doesn't want to be in.

Tests: staying out of political crossfire while dealing with both sides of the government.
DAY 4
16:00
INJECT 10BForensics

Eleven minutes in the board portal

The privileged review confirms that the CEO's credentials were used on an unrecognized laptop for eleven minutes during the Singapore trip. During that session, someone viewed a board pre-read containing the next two years of the product roadmap. The government doesn't know.

Tests: what the board owes the government, customers, and investors once it privately knows something material.
DAY 5
10:00
INJECT 11BCustomers

Hearing it from someone else

The CISO of one of Halcyon's largest cloud customers hears about the federal inquiry from her own government contacts. She asks Halcyon's chief revenue officer why the company told them nothing, and whether their shared roadmap data was exposed.

Tests: the cost of a partner learning something important from a source other than you.
DAY 6
12:00
INJECT 12BWhistleblower

"We were told to let it ship"

A member of the export-compliance team files a whistleblower complaint alleging that she raised concerns about Stratos shipments eighteen months ago and was told by a senior sales executive to let them go through.

Tests: anti-retaliation protections, and an investigation whose scope just widened beyond the CEO.
DAY 7
15:00
INJECT 13BFounder

"There's nothing to this"

On stage at a major industry conference, the CEO tells the audience there is "nothing to this" and that the reporting is a smear. The special committee had asked him not to discuss the matter publicly. His remarks are now part of the record.

Tests: managing a founder who publicly contradicts the board's own process.
DAY 8
18:00
INJECT 14BBoard conflict

A board divided

Two directors argue the board must now share the forensic findings with the government. Two long-tenured directors argue that doing so would look like an admission and could destroy the CEO. The lead independent director's credibility depends on the outcome.

Tests: whether a divided board can still make a timely, independent decision.
DAY 9
09:00
INJECT 15BDecision point

Before the subpoena

Federal officials request a meeting with Halcyon's counsel and signal that a subpoena is coming. The board must decide whether to share everything now — including the board portal access — or wait and produce only what's compelled. The board has to decide.

Tests: whether the board revisits its first decision on the merits, or only when it's out of options.
DAY 10
11:00
INJECT 16BGovernance

The board becomes the subject

Institutional shareholders send a formal demand for board records related to the CEO's relationship and the Stratos shipments. A proxy advisory firm questions whether Halcyon's board is independent enough to oversee its founder.

Tests: the board's own accountability — and whether it can show that its independence was real.

What the debrief surfaces.

The two paths are built to converge on the same hard questions, arrived at from opposite directions.

If the board brought the government in now

  • Was there a plan for protecting privilege, employees, and the CEO's personal rights before the company chose to cooperate early?
  • Was the CEO walled off from the response once his own conduct was the subject — including from the disclosure decision?
  • Did Halcyon's insider-risk program ever treat its most senior executives as potential targets?

If the board finished its investigation first

  • Was the decision to wait documented with a point at which to revisit it — and did the board revisit it when forensics confirmed the access?
  • What did waiting cost with the government, customers, and employees — and was that cost weighed up front?
  • How did the board manage a founder who spoke publicly against its own process?
Halcyon Silicon, Stratos Data Systems, and all individuals described in this scenario are fictional and created for exercise purposes only.

Want this as a PDF?

The full Halcyon scenario — every inject, both paths, and the debrief questions — is available as a print-ready PDF you can share with your own team or board. Enter your email and we'll take you straight to the download.

This is one scenario. Yours would be built around your business.

The Halcyon exercise is a sample — built to show how a leadership and insider risk simulation can branch on the decision that actually matters, and stay uncomfortable in both directions. A simulation built for your organization starts with your leadership, your insider-risk controls, and your government relationships.

Confidential by design

Exercises often require access to crisis plans, escalation structures, and vulnerabilities. That material is handled in confidence, and NDAs are available on request.

Talk to us about a custom simulation →